PHARMACEUTICALS Hope for Patients With Infectious Diseases R&D EXPANDS IN INFECTIOUS DISEASES INNOVATIVE TREATMENTS AIM TO CURE MORE PATIENTS  BREAKTHROUGH TREATMENTS A s a researcher working on hepatitis C clinical  trials around the world, Brian Woodfall, M.D.,  is only too aware of the challenges patients  face. Many endure yearlong drug treatments  only to have to undergo a liver transplant or even die from  complications related to the blood-borne virus.   “Many people don’t tolerate the current drugs very well and feel sick,” says Woodfall, Vice President of Global  Clinical Development for Tibotec  Pharmaceuticals. “And at the end of the  treatment, so many people aren’t cured.”  The current standard treatment may be  successful in less than  50  percent of  patients who have the most prevalent form  of hepatitis C, and there are no alternative  medicines for those who don’t respond. About  170  million people worldwide are infected with hepatitis C, with 3  to  4  million new cases each year,  according to the World Health  Organization. It is a common cause of  cirrhosis of the liver, liver cancer and liver transplants worldwide.  To meet this critical need, Tibotec  Pharmaceuticals is developing two new  treatments for hepatitis C. The drugs, telaprevir and TMC 435 *, have the potential to cure significantly more people  than currently available therapies and to  halve patients’ treatment time, from  12 months to six. Telaprevir was named one of  the top  10  medical innovations for  2011  by  the Cleveland Clinic. It is now undergoing  * Telaprevir is developed in collaboration with Vertex Pharmaceuticals, Inc.; TMC 435  is  developed in collaboration with Medivir AB. review by the U.S. Food and Drug Admin- istration and the European Medicines  Agency. TMC 435  is being evaluated globally  in several large Phase III trials.  “These drugs will potentially decrease  patients’ time away from work and family,  and get them back to improved health  faster,” Woodfall says. “Our research is  driven by an intense commitment to save  lives and improve patients’ health on a day-to-day basis.”  The hepatitis C medicines are among the  treatments that the Infectious Diseases and  Vaccines Therapeutic Area is developing to  address high unmet medical needs globally.  Already a world leader in HIV medicines, the franchise is developing new treatments  for tuberculosis (TB) and HIV, and has part- nered with Crucell N.V. to develop an  influenza treatment and vaccine. In February  2011 , Johnson & Johnson completed its  tender offer for Crucell, which develops  vaccines against infectious diseases world- wide. As a result, Crucell will now operate as the center for vaccines within the  Pharmaceuticals group.  “We are developing more effective treatments for infectious diseases to  improve the lives of millions of people  around the world,” says Paul Stoffels, M.D.,  Worldwide Chairman, Pharmaceuticals.  “In addition to our growing research and  development in infectious diseases,” he  adds, “we will have a greater impact on  improving human health globally with  our expansion into prevention as we build  our vaccines pipeline, particularly in  emerging markets.”  One of the world’s oldest and most deadly  infectious diseases, tuberculosis kills 1.8  million people a year. Company  researchers’ work in TB has been ground- breaking, and for the first time in more  than  40  years, a new class of drugs potentially effective against TB has been   JOHNSON & JOHNSON 2010 ANNUAL REPORT 6